MX2024013495A - Control de calidad de proteina y bag3 en el cerebro - Google Patents

Control de calidad de proteina y bag3 en el cerebro

Info

Publication number
MX2024013495A
MX2024013495A MX2024013495A MX2024013495A MX2024013495A MX 2024013495 A MX2024013495 A MX 2024013495A MX 2024013495 A MX2024013495 A MX 2024013495A MX 2024013495 A MX2024013495 A MX 2024013495A MX 2024013495 A MX2024013495 A MX 2024013495A
Authority
MX
Mexico
Prior art keywords
bag3
disease
brain
quality control
protein quality
Prior art date
Application number
MX2024013495A
Other languages
English (en)
Spanish (es)
Inventor
Arthur M Feldman
Valerie Myers
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of MX2024013495A publication Critical patent/MX2024013495A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024013495A 2022-05-03 2024-10-31 Control de calidad de proteina y bag3 en el cerebro MX2024013495A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263337914P 2022-05-03 2022-05-03
PCT/US2023/020659 WO2023215266A1 (en) 2022-05-03 2023-05-02 Bag3 and protein quality control in the brain

Publications (1)

Publication Number Publication Date
MX2024013495A true MX2024013495A (es) 2025-02-10

Family

ID=88646932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013495A MX2024013495A (es) 2022-05-03 2024-10-31 Control de calidad de proteina y bag3 en el cerebro

Country Status (11)

Country Link
US (1) US20250289858A1 (OSRAM)
EP (1) EP4518882A4 (OSRAM)
JP (1) JP2025514489A (OSRAM)
KR (1) KR20250010008A (OSRAM)
CN (1) CN119255814A (OSRAM)
AU (1) AU2023265031A1 (OSRAM)
CA (1) CA3250880A1 (OSRAM)
CL (1) CL2024003318A1 (OSRAM)
IL (1) IL316559A (OSRAM)
MX (1) MX2024013495A (OSRAM)
WO (1) WO2023215266A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4705326A1 (en) * 2023-05-02 2026-03-11 Research Institute at Nationwide Children's Hospital Gene therapy for treatment of protein misfolding diseases
CN120478386B (zh) * 2025-07-18 2025-10-17 南京大学 一种用于预防、改善和/或治疗阿尔茨海默症的siRNA及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
CA3228845A1 (en) * 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction
CN109937045A (zh) * 2016-08-11 2019-06-25 天普大学-联邦高等教育系统 局部缺血/再灌注损伤
CN113286588A (zh) * 2018-10-19 2021-08-20 阿克里普斯一有限公司 神经性疾病的治疗
US20220023350A1 (en) * 2018-11-04 2022-01-27 Figene, Llc Treatment of cerebral hypoxia including stroke, chronic traumatic encephalopathy, and traumatic brain injury
WO2020150377A1 (en) * 2019-01-15 2020-07-23 Temple University - Of The Commonwealth System Of Higher Education Targeting the bag family for the treatment of neurodegenerative disease
WO2023069744A1 (en) * 2021-10-22 2023-04-27 Temple University Of The Commonwealth System Of Higher Education Bag3 methods and uses for treatment of inflammation

Also Published As

Publication number Publication date
EP4518882A4 (en) 2026-04-22
WO2023215266A1 (en) 2023-11-09
EP4518882A1 (en) 2025-03-12
CN119255814A (zh) 2025-01-03
CL2024003318A1 (es) 2025-03-21
JP2025514489A (ja) 2025-05-02
AU2023265031A1 (en) 2024-11-28
US20250289858A1 (en) 2025-09-18
IL316559A (en) 2024-12-01
KR20250010008A (ko) 2025-01-20
CA3250880A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
CL2024003318A1 (es) Control de calidad de proteína y bag3 en el cerebro
ATE125701T1 (de) Gabapentin und dessen derivate zur behandlung neurodegenerativer krankheiten.
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
MX2023001840A (es) Agonistas de bicicloheptano pirrolidina de los receptores de orexina.
PH12022552738A1 (en) Compositions comprising nanoparticles, method of making and uses thereof
MX2022001084A (es) Metodo de tratamiento de la enfermedad de alzheimer mediante la regulacion de microrganismos intestinales.
MX2020014203A (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurológicos.
WO2022020391A3 (en) Precision targeted retromer therapeutics for the treatment of neurodegenerative diseases and disorders
PH12020551779A1 (en) Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
RS67760B1 (sr) Kanabinoidna kompozicija i njena primena u pripremi leka za lečenje neurodegenerativnih bolesti kao što su parkinsonova bolest i alchajmerova bolest
EP4370131A4 (en) METHODS FOR TREATING ALZHEIMER'S DISEASE
WO2023178280A3 (en) Compositions and methods for modulating alpha-synuclein expression
WO2019075456A3 (en) Methods and substances for prevention and treatment of neurodegenerative diseases
WO2021226439A3 (en) Engineered relaxins and methods of use thereof
ZA202304463B (en) Methods for delivering medium chain triglycerides with controlled pharmacokinetic, safety and tolerability profiles
EP4327884A3 (en) 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune diseases
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
EP4087654A4 (en) TREATMENT OF ALZHEIMER'S DISEASE
NZ780966A (en) Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
MX2025014100A (es) Composiciones para el tratamiento de trastornos neurologicos
HK40098773A (en) Compositions and methods for the treatment of alzheimer's disease
IL315725A (en) Methods and preparations for the treatment of Parkinson's disease
HK40111619A (en) Methods of treating alzheimer's disease
SI1330468T1 (sl) Ĺ˝veplovi analogi 21-hidroksi-6,19-oksido-progesterona (21oh-6op) za zdravljenje preseĺ˝ka glukokortikoidov
HK40105418A (en) Use of aprepitant for treating alzheimer's disease